Perfusion Change of Hepatocellular Carcinoma During Atezolizumab plus Bevacizumab Treatment: A Pilot Study

ConclusionThe early change in HCC perfusion may predict the long-term therapeutic response to atezolizumab plus bevacizumab, promoting personalized treatment for HCC patients.
Source: Journal of Gastrointestinal Cancer - Category: Cancer & Oncology Source Type: research